4547:TYO
Kissei Pharmaceutical Co Ltd
3 685,00 JP¥
arrow_downward
-0,41%(-15,00) 1D
5 қаз., 11:19:06 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
3 705 JP¥
High
3 720 JP¥
Low
3 670 JP¥
Mkt. cap
171,51 млрд
Avg. vol.
68,01 мың
Volume
32,50 мың
Dividend
3,26%
Quarterly dividend
30 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
10,92
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 мың
Open
3 705 JP¥
High
3 720 JP¥
Low
3 670 JP¥
Mkt. cap
171,51 млрд
Avg. vol.
68,01 мың
Volume
32,50 мың
Dividend
3,26%
Quarterly dividend
30 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
10,92
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 мың
News stories
From web sources and news partners
Moomoo
·
1 сағат бұрын
The Next Generational AI Monopoly: Why Rezolve AI ($RZLV) is a Screaming Buy Before a 10x Repricing
Simply Wall Street
·
1 сағат бұрын
October 2026 Founder Led Stocks To Watch
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 мың
Founded1946 ж. 09 там.
HeadquartersMatsumoto, Nagano, Жапония
SectorPharmaceutical industry
Websitekissei.co.jp